ALLO Allogene Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLO

Price (delayed)

$5.49

Market cap

$793.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.32

Enterprise value

$721.09M

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
Allogene Therapeutics's debt has plunged by 100% from the previous quarter
ALLO's revenue has dropped by 99% year-on-year
The gross profit has dropped by 99% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allogene.com
Peers: OVID

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
144.5M
Market cap
$793.29M
Enterprise value
$721.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
3,234.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,967.47
Earnings
Revenue
$243,000
EBIT
-$332.63M
EBITDA
-$318.34M
Free cash flow
-$225.71M
Per share
EPS
-$2.32
Free cash flow per share
-$1.58
Book value per share
$4.62
Revenue per share
$0
TBVPS
$5.71
Balance sheet
Total assets
$817.08M
Total liabilities
$151.21M
Debt
$0
Equity
$665.87M
Working capital
$474.31M
Liquidity
Debt to equity
0
Current ratio
9.7
Quick ratio
9.68
Net debt/EBITDA
0.23
Margins
EBITDA margin
-131,002.9%
Gross margin
100%
Net margin
-136,885.6%
Operating margin
-138,044.9%
Efficiency
Return on assets
-36.8%
Return on equity
-43.4%
Return on invested capital
-39.9%
Return on capital employed
-43.6%
Return on sales
-136,885.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
-0.36%
1 week
-3.68%
1 month
-23.75%
1 year
-39%
YTD
-12.72%
QTD
-12.72%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$243,000
Gross profit
$243,000
Operating income
-$335.45M
Net income
-$332.63M
Gross margin
100%
Net margin
-136,885.6%
ALLO's revenue has dropped by 99% year-on-year
The gross profit has dropped by 99% year-on-year
ALLO's operating income is down by 31% year-on-year and by 7% since the previous quarter
The net income has decreased by 29% YoY and by 6% QoQ

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
1.19
P/S
3,234.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,967.47
The EPS has contracted by 23% YoY and by 5% from the previous quarter
ALLO's price to book (P/B) is 68% less than its 5-year quarterly average of 3.7 and 34% less than its last 4 quarters average of 1.8
Allogene Therapeutics's equity has decreased by 27% YoY and by 10% QoQ
ALLO's revenue has dropped by 99% year-on-year
The stock's price to sales (P/S) is 43% less than its last 4 quarters average of 5721.6

Efficiency

How efficient is Allogene Therapeutics business performance
The return on equity has dropped by 68% year-on-year and by 15% since the previous quarter
The return on assets has dropped by 59% year-on-year and by 13% since the previous quarter
ALLO's return on invested capital is down by 36% year-on-year and by 10% since the previous quarter
The ROS has contracted by 8% from the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
The total liabilities has increased by 24% year-on-year and by 2.4% since the previous quarter
The company's total assets fell by 21% YoY and by 8% QoQ
Allogene Therapeutics's debt is 100% less than its equity
Allogene Therapeutics's debt has plunged by 100% from the previous quarter
The company's debt to equity has shrunk by 100% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.